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Interleukin (IL)-4 is a cytokine known mainly for its anti-inﬂammatory activity. Using the in vivo murine air pouch model, we
found that IL-4 signiﬁcantly increased the number of leukocytes after 9 hours of treatment, consisting mainly of neutrophil (60%)
and monocytic (40%) cell populations. Using an antibody array, we found that the expression of several analytes (predominantly
CCL2) was increased by IL-4 before the arrival of leukocytes. The IL-4-induced expression of CCL-2 was conﬁrmed by ELISA.
Air pouch resident lining cells were harvested and were found to express IL-4Rα. CCL2 mRNA expression was monitored in
lining cells, cells isolated from the air pouch skin, in RAW264.7 macrophage and in epithelial Mode-K cells and its expression was
increased in response to IL-4 in all conditions. We conclude that IL-4 can attract leukocytes in vivo by an indirect mechanism
involving the production of several analytes by, at least, resident cells.
Copyright © 2009 Claude Ratth´ e et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Neutrophils are the ﬁrst blood leukocytes to arrive to an
inﬂammatorysite.Theprocessoftransendothelialmigration
fromthebloodtothetissueiscomplexandinvolvesresponse
to chemotactic factors and binding to adhesion molecules
at the endothelium surface [1]. These events permit the
extravasation of blood neutrophils to the tissue where they
can perform diﬀerent functions. Major roles of neutrophils
include phagocytosis, production of reactive oxygen species,
and production of chemoattractants such as IL-8, which
recruit further competent cells [2]. Neutrophil response
usually terminates when neutrophils undergo apoptosis and
are phagocytosed by arising macrophages [3]. However, in
certain inﬂammatory diseases, such as rheumatoid arthritis
or inﬂammatory bowel diseases, neutrophils persist at the
inﬂammatorysite,andperpetuatingtheinﬂammation[4,5].
Interleukin-4 (IL-4) is a member of the CD132-
dependent cytokines which also comprises IL-2, -7, -9, -15
and -21 [6]. There are two distinct IL-4 receptors: type I,
whichiscomposedofIL-4RαandCD132(IL-2Rγ orγc),and
type II receptor, composed of IL-4Rα and IL-13Rα1 chains
[7]. IL-4 has largely been associated with anti-inﬂammatory
functions since it decreases monocyte and macrophage
functions [8, 9] and induces a Th2 type response. However,
IL-4 can also be considered as proinﬂammatory, since its
expression and a Th2 type response are associated with
allergies and asthma [10], but it is still regarded mainly as an
anti-inﬂammatory cytokine. IL-4 was also found to possess
other proinﬂammatory functions, such as the recruitment of
inﬂammatory cells by increasing the expression of VCAM-1
on the endothelial surface [11] and increasing eosinophils,
macrophages and B cells chemoattraction [12–14]. This
dual role can be of great importance for ameliorating
or developing alternative therapies. For instance, IL-4
has been considered as a candidate for the treatment of
rheumatoid arthritis, since it induces a Th2 biased response
[15]. Paradoxically, other studies showed that IL-4 is
implicated in the development of inﬂammatory arthritis
[16], demonstrating the need for a better understanding of
IL-4 proinﬂammatory functions.
Neutrophils are known to express the type I IL-4R (IL-
4Rα/CD132) but not the type II IL-4R (IL-4Rα/IL-13Rα1)
[17–19]. Interestingly, IL-4 may possess both pro- and2 Mediators of Inﬂammation
anti-inﬂammatory roles in neutrophils. For example, IL-4
induces production of an IL-1R antagonist considered to be
an anti-inﬂammatory cytokine that blocks IL-1 eﬀects [20].
The proinﬂammatory activity of IL-4 includes its ability to
delay neutrophil apoptosis and the fact that it increases neu-
trophilIL-8production[17],contributingtotherecruitment
of other leukocytes to site of inﬂammation. Studies have
shown that the presence of neutrophils in asthma conjugated
with increased IL-4 concentrations contribute to the severity
of the disease [21, 22]. Even if many aspects of IL-4 eﬀects on
neutrophilshavebeenstudied,theabilitytoattractthesecells
in vivo is not well understood. In this study, we report that
IL-4 possesses proinﬂammatory activities as judged by its
ability to attract leukocytes in vivo and the local production
of several proinﬂammatory molecules.
2.MaterialsandMethods
2.1. Chemicals and Agonists. Recombinant murine IL-4 was
purchased from R&D systems Inc (Minneapolis, MN).
Lipopolysaccharide (LPS; from Escherichia coli 0111.B4) was
purchased from Sigma Chemical Co. (St-Louis, MO), and
Isoﬂurane was purchased from Pharmaceuticals Partners of
Canada Inc (Richmond Hill, Ontario).
2.2. Neutrophils Isolation. Neutrophils were isolated from
the venous blood of healthy volunteers by dextran sedi-
mentation followed by centrifugation over Ficoll-Hypaque
(GE Healthcare, Baie d’Urf´ e, Quebec, Canada) as previously
described [19, 23, 24]. Blood donations were obtained from
informed and consenting individuals according to institu-
tionally approved procedures. Cell viability was monitored
by trypan blue exclusion, and the purity (>98%) was veriﬁed
by cytology from cytocentrifuged preparations coloured by
Hema-stain.
2.3. Murine Air Pouch Model. C 5 7 B L / 6m i c e ,6t o8w e e k s
of age, were obtained from Charles River Laboratories (St-
Constant, Canada). On days 0 and 3, mice were anaes-
thetized with isofurane and 3ml of sterile air was injected
subcutaneously, in the back, with a 26-gauge needle to form
an air pouch as published previously [25, 26]. On day
6, 1ml of the following was injected into the air pouch:
sterile HBSS, the positive control LPS (1μg/ml) or murine
IL-4 (250ng/ml), an optimal concentration determined
previously when testing the eﬀect of IL-4 in vitro [19]. In
addition, this concentration was selected for comparison
with those previously observed with IL-15 using the same in
vivo model [25]. Mice were killed by CO2 asphyxiation 3, 6,
9, 12 or 24 hours after the treatment and the pouches were
washed once with 1ml and then twice with 2ml of HBSS
containing10mMEDTA.Exudateswerecentrifugedat100×
g for 10 minutes at room temperature and supernatants
were collected and stored at −80◦C for further analysis.
Cells were resuspended at 0.5 × 106 cells/ml, centrifuged,
spread onto microscope slides and stained with Hema-Stain
for quantiﬁcation of leukocyte subpopulations. To further
characterize the leukocyte subpopulations, the cells were
suspended in PBS containing 5μg/ml human IgG for 30
minutesat4◦CtoblockFcRsandthenstainedfor30minutes
at 4◦C with puriﬁed rat antimouse 7/4 mAb directed against
murine neutrophils or rat antimouse F4/80 Ag Ab directed
against murine monocytes macrophages. Experiments were
performed under protocols approved by Animal Use and
Care Committees at INRS-Institut Armand-Frappier.
2.4. Cytokine/Chemokine Protein Array. Mouse inﬂamma-
tion antibody array I kit was purchased from Chemicon
International (Temecula, CA) and all the steps for the
simultaneous detection of 40 analytes were performed as per
the manufacturer’s recommendation. Previous experiments
conducted with two membranes probed with the exudates
from two diﬀerent mice treated with LPS reveal that the
results were reproducible (data not shown). Because of that,
we next decide to pool exudates (n ≥ 13 mice) harvested
from HBSS-treated (control) or IL-4induced murine air
pouches to probe the membranes no more than two
weeks after the in vivo experiments. The chemiluminescent
signal from the bound cytokines/chemokines present in the
exudates was detected on Kodak ﬁlm X OMAT-RA. The
signal intensity (each analytes in duplicate) of each spot was
normalized to the membrane’s positive control (four spots).
Results are expressed as ratios (tested group/control). Ratios
≥1.2 were considered slightly positive and those ≥1.5 were
considered strongly positive. Protein array membranes were
scanned and densitometry analysis was performed using the
Multi-Analyst program (Bio-Rad, Hercules, CA).
2.5. Detection of Murine CCL2 by ELISA. Fluids were
harvested from air pouches after 6, 9, 12 and 24 hours
of treatment with buﬀer or IL-4 and were pooled, corre-
spondingly. CCL2 was quantiﬁed using the commercially
available enzyme-linked immunosorbent assay (ELISA) kits
for murine CCL2 (R&D systems Inc, sensitivity of <2pg/ml)
according to the manufacturer’s recommendations. Samples
were tested at least in duplicate.
2.6. Air Pouch Resident Cells. Air pouches were created on
the back of C57BL/6 mice as previously described and
cells lining the air pouch were harvested and stimulated
using two diﬀerent methods. First, 1ml of trypsin-EDTA
was injected in the pouches. After 5 minutes, cells were
collected (hereafter referred to as lining cells) and the
pouches were washed twice with 2ml of HBSS-EDTA. Cells
werecentrifugedandincubated(10×106 cells/ml)withHBSS
or 250ng/ml IL-4 for 6 hours. Cells were harvested and lysis
and RNA extraction were performedas previously described.
Second, 1ml of HBSS or IL-4 was injected in the pouches.
After 6 hours, the skin of the pouch was cut and the ﬁrst
layer of cells lining cells was manually removed and snap-
frozen in liquid nitrogen (hereafter referred as skin cells).
Tissues were mechanically crushed in liquid nitrogen using a
pestle and mortar. Lysis and RNA extraction were performed
as described [19].
2 . 7 .R e v e r s eT r a n s c r i p t i o na n dP o l y m e r a s eC h a i nR e a c -
tion (PCR). Cells (10 × 106 cells/ml in RPMI-Hepes-P/SMediators of Inﬂammation 3
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Figure 1: IL-4 induces inﬂammation in vivo. Murine air pouches
were raised before injection of buﬀer (Ctrl) or 250ng/ml IL-4 and
exudates were harvested at the indicated periods of time and the
numberofleukocyteswascalculated.Resultsaremeans ±SEM(n ≥
6). ∗P<. 05 versus Ctrl.
containing 10% fetal calf serum) were stimulated or not
for 6 hours at 37◦C with HBSS, or 250ng/ml IL-4.
Cells were harvested, washed three times with HBSS and
RNA extraction was performed using the Absolutely RNA
Miniprep Kit (Stratagene, La Jolla, CA) according to the
manufacturer’s protocol. The reverse transcription reaction
was performed using 0.5μgo fR N Aa n d2 0 0 Uo ft h eM -
MLV enzyme in the following PCR buﬀer reaction: 5mM
MgCl2,1mMdNTP(dATP.dCTP,dGTP,dTTP),40URnase
inhibitor, 0.03U hexamer. PCR reactions were performed
using the newly made cDNA, 0.5U Taq Polymerase and the
following primers: upstream: 5 -tccatgcaggtccctgtcatg-ctt-3 ,
downstream: 5 -ctagttcactgtcacactggtc-3  for CCL2 (MCP-
1); upstream: 5 -ctggcacctggagtgagtgg-3 ,d o w n s t r e a m5  -
acagcgcaccacact-gacact-3  for IL-4R (IL-4Rα); upstream:
5 -agagcaagcaccatgttgaaacta-3 , downstream tgggatcacaag-
attctgtaggtt for IL-2RG (CD132); upstream: 5 -tccgataac-
gaacgagactc-3 ,d o w n s t r e a m :5  -cagggacttaatcaacgcaa-3  for
the 18S control. Samples were loaded onto a 1.5% agarose
gel containing 0.006% ethidium bromide. The bands were
visualized using the Biorad Bioscan with a UV lamp and the
results were analyzed using the Multi-Analyst program.
2.8. Cell Culture. Raw 264.7 and Mode-K cells were cultured
in RPMI-1640 medium supplemented with 10% fetal calf
serum, 2.5% 1M HEPES, 50U/ml penicillin, and 50μg/ml
s t r e p t o m y c i n .C e l l sw e r eg r o w na t3 7 ◦C, in a 5% CO2
incubator at concentrations ranging from 0.2 × 106 cells/ml
to 1 × 106 cells/ml. Cells were grown to conﬂuence in 6 well
microplates and stimulated with HBSS or IL-4 for 6 hours at
37◦C. Cellswerescrapedand washedtwicewithHBSSbefore
performing lysis and RNA extraction as previously described
[19].
2.9. Statistical Analysis. Statistical analysis was performed
with SigmaStat for Windows Version 3.00 (Copyright 1992–
2003 SPSS Inc.) using a one-way analysis of variance
(ANOVA). Statistical signiﬁcance was established at P<. 05.
3. Results
3.1. ProInﬂammatory Eﬀects of IL-4 In Vivo. Previous studies
demonstrated that IL-4 induces chemoattraction of diﬀerent
cell types such as eosinophils, macrophages, ﬁbroblasts and
B cells [27]. Here, we decided to investigate the ability of IL-4
to induce migration of neutrophils in vivo using the murine
air pouch model. In this model, LPS is known to induce
a potent acute inﬂammation peaking between 6–9 hours,
consisting mainly in the recruitment of neutrophils (80–
100%) disappearing (by a mechanism that remains unclear)
after 12–24 hours [26]. Recently, using this model, we have
identiﬁed that two other CD132-dependent cytokines, IL-
15 and IL-21, can attract leukocytes in this model after 6–
9h o u r s[ 25, 26], but unlike LPS, the response was less
potent and these cytokines attract two major cell population:
neutrophils(∼60%)andmonocyticcells(∼40%).Therefore,
we performed kinetic experiments from 3 hours to 24 hours.
As shown in Figure 1, after 3 hours, the basal level of total
leukocytes observed in control mice receiving the buﬀer was
0.56 ± 0.07 × 106 cells/pouch (mean ± SEM) and was not
increased by IL-4, eliminating the possibility that a rapid
leukocyte inﬂux occurs at earlier time points. However, after
9 hours of treatment, the number of leukocytes attracted by
IL-4 was signiﬁcantly increased when compared to control
(1.5±0.07×106 for IL-4 versus 0.67±0.03×106 cells/pouch
for control). Thus IL-4 induces migration of leukocytes in
vivo. As expected, the leukocyte inﬁltration induced by IL-4
disappears overtime, and the number of attracted leukocytes
returned to the basal level after 24 hours.
Because the two main leukocyte populations present
in the exudates of the acute inﬂammation induced in the
murine air pouch model by two other CD132-dependent
cytokines, IL-15 and IL-21, are neutrophil and monocytic
populations,weperformedﬂowcytometryexperimentswith
speciﬁc antibodies recognizing these two subpopulations.
As shown in Figure 2(a), about 60% of cells attracted by
IL-4 are neutrophils and 40% are monocytes macrophages.
These results were conﬁrmed by cytology (Figure 2(b)). As
expected, more than 80% of cells attracted by LPS were
neutrophils.
3.2. IL-4 Induces the Local Production of Several Analytes
(Cytokines/Chemokines) In Vivo; Predominance of CCL2.
Because of the previous results we performed an antibody
array in order to monitor simultaneously 40 diﬀerent ana-
lytes associated with inﬂammation in kinetic experiments.4 Mediators of Inﬂammation
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Figure 2: IL-4 induces the recruitment of neutrophil and monocytic cells in vivo. Murine air pouches were created and buﬀer, IL-4
(250ng/ml) or LPS (1μg/ml) was administered for 9 hours as described in Materials and Methods. (a) cell populations were identiﬁed
by ﬂow cytometry (n ≥ 6) after staining with puriﬁed rat antimouse 7/4 mAb directed against murine neutrophils (neutro, open curve) or
rat antimouse F4/80 Ag Ab recognizing murine monocyte/macrophages (mono, open curve) as described in Materials and Methods. Inset,
representative data plotted in the bar graph, where the grey curves illustrate the appropriate isotypic controls. (b) cell identiﬁcation was
conﬁrmed by cytology. Results are from one representative experiment out of at least 6.
However, because we treated the mice with IL-4, and since
this cytokine is among the tested analytes, we deliberately
eliminated the corresponding data. Therefore, the total
number of analytes is 39. As illustrated in Table 1, the levels
of cytokine and chemokine expression detected after 3 hours
of treatment with IL-4 were equivalent or even inferior to
those obtained from control animals. However, after 6 hours
of treatment with IL-4 the ratios of 14 of 39 analytes were
above the level of control set to 1. Among these, 4 of 14
(CCL2/MCP-1, CXCL5/LIX, MIG and sTNFRI) exhibited
ar a t i o≥ than 1.2 (arbitrary selected). CCL2 is the most
predominant chemokine detected in the exudates of IL-4-
induced air pouches with a ratio of 7.25, followed by CXCL5,
MIG and sTNFRI, with a ratio of 1.65, 1.46 and 1.46,
respectively. After 9 hours of treatment, 23 of 39 analytes
presented a ratio greater than controls. Among these, 17 of
22 analytes presented a ratio ≥ 1.2. In contrast to the 6
hourstimepoint,therewerenoanalytesdetectedwitharatio
greater than 4. In fact, it appears rather that there are more
analytes present in the exudates with a ratio ranging from
1.2–2.0.IL-12p70andIL-13arethetwocytokinesdetectedin
greaterconcentrationswithratiosof2.1and2.0,respectively.Mediators of Inﬂammation 5
Table 1: Analysis of the diﬀerent analytes detected in the cell free exudates harvested from IL-4-induced air pouch1.
Analyte 3 hours 6 hours 9 hours 12 hours
BLC 0.23 1.10∗ 0.86 nd
CD30L 0.47 nd 1.71∗ nd
Eotaxin 0.70 1.10∗ 1.29∗ nd
Eotaxin-2 0.70 0.85 1.36∗ 0.72
Fas Ligand 0.23 0.55 0.43 nd
Fractalkine 0.16 0.55 1.00 nd
G-CSF 0.31 nd 1.20∗ nd
GM-CSF 0.93 1.10∗ 0.43 0.36
IFNγ 0.47 1.10∗ 0.64 nd
IL-1α nd 1.10∗ 0.96 0.72
IL-1β nd nd 0.86 nd
IL-2 nd nd 0.86 nd
IL-3 nd 1.10∗ 1.71∗ nd
IL-6 nd nd 1.71∗ nd
IL-9 nd 0.55 1.71∗ nd
IL-10 nd nd 1.71∗ nd
IL-12 p40/p70 0.35 0.55 1.03∗ nd
IL-12p70 0.23 nd 2.00∗ 0.72
IL-13 0.93 1.10∗ 2.14∗ 0.72
IL-17 0.47 0.55 0.86 nd
I-TAC nd 1.10∗ 1.20∗ 0.72
KC nd 0.55 1.71∗ 1.44∗
Leptin nd 1.10∗ 1.50∗ 1.44∗
LIX/CXCL5 0.93 1.65∗ 0.95 0.72
Lymphotactin nd 0.70 1.19∗ 0.72
MCP-1/CCL2 0.47 7.25∗ 1.54∗ nd
M-CSF nd nd 1.29 0.72
MIG nd 1.46∗ 0.94 nd
MIP-1α 0.47 0.37 1.71∗ 1.44∗
MIP-1γ 0.58 1.17∗ 1.05∗ 1.15∗
RANTES 0.78 0.55 1.16∗ 0.12
SDF-1 0.47 nd 0.86 0.36
TCA-3 0.70 0.55 0.86 0.72
TECK nd nd 0.86 nd
TIMP-1 0.23 0.78 1.04∗ nd
TIMP-2 0.47 nd 1.29∗ nd
TNF-α nd 0.55 0.86 0.72
sTNFR I 0.45 1.46∗ 0.97 1.08∗
sTNFR II nd 0.55 0.86 nd
1Air pouches were created and 250ng/ml IL-4 or buﬀer was administered into the pouch for the indicated periods of time. Pooled exudates (n ≥ 13 mice)
were used to probe the membranes (Mouse inﬂammation antibody array I) no more than two weeks after the in vivo experiments. Results are calculated as
ratios, as described in Materials and Methods. nd, not detectable; ∗, ratio above 1; numbers in bold characters, ratio ≥ 1.2.
After 12 hours, only 5 of 39 analytes exhibited a ratio above
1 and only three, KC, leptin and MIP-1α,h a dar a t i og r e a t e r
than 1.2, each at 1.44.
3.3. IL-4 Increases CCL2 Protein Expression In Vivo. Because
of the above results, we next focused on CCL-2. In order to
conﬁrm the results obtained by the antibody array assay, the
exudates were tested by a speciﬁc ELISA for murine CCL-2.
AsillustratedinFigure 3,theconcentrationofCCL2detected
in the pooled air pouch ﬂuids (n ≥ 7 mice) was increased by
IL-4 when compared to controls. Interestingly, at the 6 hours
and 9 hours time points, the concentration of CCL2 was 975
(IL-4) versus 167 (control) pg/ml for a ratio of 5.8 and 288
(IL-4) versus 214pg/ml for a ratio of 1.4, respectively. These6 Mediators of Inﬂammation
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Figure 3: IL-4 increases CCL2 protein expression in the exudates.
Air pouches was created as described in Materials and Methods and
1mlofthebuﬀer (Ctrl), LPS (1μg/ml), or IL-4 (250ng/ml) were
administered into the pouch. Exudates were harvested after 6, 9,
12 and 24 hours, pooled (n ≥ 7) and then CCL2 production was
measured by ELISA.
values are close to the ratios obtained by the antibody array
assay (7.25 and 1.54, resp.). Of note, CCL2 was not detected
after 12 hours. LPS was used as a positive control.
3.4. Expression of IL-4R in Murine Air Pouch Lining Cells
and Production of Cytokines in Response to IL-4. Because
several analytes detected in the exudates of IL-4-induced air
pouch were present before the emigration of leukocytes, and
since most of them are not necessarily typical neutrophil
or monocyte chemoattractants, it is highly plausible that
the lining or resident cells from the pouch are the ﬁrst
to interact with IL-4. Therefore, we isolated the lining
cells from air pouches and investigated the expression of
IL-4R. As illustrated in Figure 4 the lining cells expressed
both CD132 (IL-2Rγ) and IL-4Rα, as assessed by RT-PCR
(Figure 4(a)). We conﬁrmed the expression of IL-4Rα at the
cell surface of lining cells by ﬂow cytometry (Figure 4(b)).
Of note, expression of this component alone is suﬃcient
to induce a signal in response to IL-4. Knowing that the
harvested lining cells express the IL-4R, we next stimulated
them in vitro (pool of n = 9) with IL-4 for 6 hours
and investigated the expression of the same analytes. As
illustrated in Table 2,2 0o f3 9a n a l y t e sw e r ed e t e c t e dw i t h
a ratio greater than 1. Among these, 5 (Eotaxin-2, G-CSF,
MIG, SDF-1 and sTNFR-I), exhibited a ratio ≥ 1.2. Of note,
CCL2 was only detected at a ratio of 1.12. This suggests that
the high level expression of several analytes observed in vivo
in IL-4-induced air pouch necessitates other factors and/or
players. Thus, the proﬁle of analytes detected after 6 hours
Table 2: Analysis of the diﬀerent analytes detected in the super-
natant harvested from IL-4-induced lining cells1.
Analyte 6 hours
BLC 0.36
CD30L 0.54
Eotaxin 0.54
Eotaxin-2 2.92∗
Fas Ligand 0.36
Fractalkine 1.08∗
G-CSF 1.20∗
GM-CSF 0.72
IFNγ 1.08∗
IL-1α 0.98
IL-1β 1.08∗
IL-2 1.08∗
IL-3 1.08∗
IL-6 0.85
IL-9 1.08∗
IL-10 1.08∗
IL-12 p40/p70 0.81
IL-12p70 0.81
IL-13 0.72
IL-17 0.54
I-TAC 1.08∗
KC 1.14∗
Leptin 1.08∗
LIX/CXCL5 0.99
Lymphotactin 0.54
MCP-1/CCL2 1.12∗
M-CSF 0.54
MIG 2.16∗
MIP-1α 1.08∗
MIP-1γ 1.03∗
RANTES 0.52
SDF-1 2.16∗
TCA-3 0.75
TECK 0.54
TIMP-1 0.65
TIMP-2 1.08∗
TNF-α 0.54
sTNFR I 1.24∗
sTNFR II 1.08∗
1 Air pouches were created and lining cells were harvested. pooled and
incubated in vitro with 250ng/ml IL-4 for 6 hours. The supernatant was
used to probe the membranes (Mouse inﬂammation antibody array I) no
more than two weeks after the in vivo experiments. Results are calculated as
ratios, as described in Materials and Methods. ∗, ratio above 1; numbers in
bold characters, ratio ≥ 1.2.
in response to IL-4 diﬀers in terms of expression level and
in terms of speciﬁcity in vivo and in vitro, suggesting that
other cells are involved and that the responses are context
speciﬁc. Because CCL2 is the predominant analyte detected
in the exudates in response to IL-4, and in order to betterMediators of Inﬂammation 7
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Figure 4: The murine air pouch resident lining cells express the IL-4 receptor. Air pouches were created and lining cells were harvested
as described in Materials and Methods. IL-4Rα chain was detected by RT-PCR (a) and by ﬂow cytometry (b) using a speciﬁc antibody
directed against murine IL-4Rα.N o t et h a tI L - 4 R α mRNA was detected at variable levels in all tested animals, as well as IL-2Rγ. Only four
diﬀerentanimalsarepresented(nos.1–4).Thereceptorwasdetectedonthecellsurfaceoftheliningcells.Resultsarefromonerepresentative
e x p e r i m e n to u to f4 .
elucidate the participation of diﬀerent cell populations for
such production, we ﬁrst veriﬁed the possibility that the
attracted leukocytes themselves participate in the increased
production of CCL2. As illustrated in Figure 5(a),l e u k o c yt e s
attracted by IL-4 can produce higher levels of CCL2 mRNA
whencomparedtocontrols.Wenext collectedthelining cells
andtheskincellsfromtheinsidepartoftheairpouchtreated
with buﬀer or IL-4 and monitored the gene expression of
CCL2. In addition, we investigated the gene expression of
CCL2 in murine RAW 264.7 macrophages and epithelial
Mode-Kcells.AsillustratedinFigure 5(b),IL-4increasedthe
CCL2 mRNA expression in all conditions when compared to
controls. Thus, according to the results obtained for CCL2,
the production of the diﬀerent analytes induced by IL-4
could originate from resident cells expressing IL-4R, as well
as from leukocytes attracted by IL-4.
4. Discussion
SeveralmembersoftheCD132-dependentcytokines,includ-
ing IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21, are involved in
diverse inﬂammatory disorders [18]. Among these, IL-4 is
best known for its anti-inﬂammatory activity. For example,
IL-4 was found to induce production of interleukin-1 recep-
torantagonist(IL-1Ra)inneutrophils[28]andtoantagonize
the biological action of IL-1 by inducing the expression and
r e l e a s eo fI L - 1t y p eI Id e c o yr e c e p t o r[ 29]. In addition, IL-4
was found to inhibit LPS-induced prostaglandin E2(PGE2)
as well as LPS-induced cyclooxygenase-2 (COX-2) protein
expression in neutrophils [30]. Consistent with its anti-
inﬂammatory properties, Wertheim and colleagues [31]
reported that IL-4 inhibited IL-8 production, but this was
observed in LPS-primed neutrophils. In contrast, we have
demonstrated that IL-4 can directly increase IL-8 production
in human neutrophils [17]. The identiﬁcation of IL-4 as
a neutrophil agonist is not recent. For example, more
than 18 years ago, Boey and colleagues [32] reported that
IL-4 enhanced neutrophil-mediated killing of opsonized
bacteria. It is clear that the biological activity of IL-4 in
neutrophils reported in the literature is far from complete. In
addition, its proinﬂammatory activity remains to be better
elucidated.
Using the murine air pouch model, we demonstrate that
IL-4 possesses proinﬂammatory activity in vivo based on
its ability to attract leukocytes, including neutrophils. It is
important to mention that very few studies have investigated
the ability of IL-4 itself to promote an inﬂammatory
response in vivo. However, in one study, IL-4 was found to
induce leukocyte recruitment in vivo using the cremasteric
postcapillary venule model. Also, although IL-4 was found
to attract eosinophils, monocytes and lymphocytes in this
model, no neutrophils were attracted. Interestingly, other
CD132-dependent cytokines, including IL-15 and IL-21,
were previously found to attract leukocytes in vivo in this
model [25, 26]. As for IL-4, IL-15 is known as a neutrophil
agonist but, unlike these two cytokines, we recently docu-
mented that IL-21 does not modulate a panel of neutrophil
functions and this was correlated with the absence of the
IL-21Rα subunit in these cells [26]. Also, even if IL-21 is
not a direct neutrophil agonist, this cytokine was found to
attract neutrophil and monocytic cell populations in vivo.
WhileIL-15wasfoundtoincreasethelocalproductionofIL-
6 and MIP-2 (CXCL2) into the cell-free air pouch exudates,
IL-21 did not. Moreover, IL-21 did not increase CCL3
(MIP-1α) and CCL5 (RANTES) production. This suggests
that diﬀerent cytokines and chemokines are involved in the
neutrophil recruitment and that resident cells, in the case of8 Mediators of Inﬂammation
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Figure 5: Expression of CCL2 mRNA in diﬀerent cell populations. (a) air pouches were created and IL-4 or buﬀer was administered for 6
hours. Cells were harvested, pooled (n = 6) and CCL2 (MCP-1) mRNA were detected as described in Materials and Methods. (b) Murine
air pouches were created and the lining cells and skin cells were harvested as described in Materials and Methods. Lining cells, skin cells,
murine macrophages (RAW) and epithelial Mode-K cells were stimulated for 6 hours with buﬀer (Ctrl) or 250ng/ml IL-4 and the expression
of CCL2 mRNA was performed by RT-PCR. Results are from one representative experiment out of at least 3. Number between parentheses
represents the ratio of the signal intensity of (IL-4/18S)/Ctrl/18S) obtained after densitometry analysis using a Fluor-S multi-imager (Bio-
Rad, Hercules, CA) and the Multi-Analyst version 1.1 program.
IL-21, play an important role. Here, using an antibody array
assay, we found that administration of IL-4 into air pouch
increased local production of several analytes. Interestingly,
the production of CCL2, CXCL5, MIG and sTNFR I were
detected in higher concentrations in IL-4-treated pouches
before the total leukocyte counts were signiﬁcantly increased
versus controls. Thus, IL-4 cannot only directly attract
neutrophils in vitro; it can also act indirectly in vivo. Results
from Wan and colleagues are in agreement with this latter
point [33]. They found that CCL2, a chemokine previously
thought to attract leukocytes other than neutrophils, could
enhance leukocyte rolling, adhesion and recruitment in
vivo using intravital microscopy of the mouse cremaster
microcirculation system where about 85% of cells attracted
were neutrophils. As stated by the authors, endothelial cells
were probably not involved, based on the inability of CCL2
to increase P-selectin expression in these cells. They propose
an indirect eﬀect involving activation of an intermediary
tissue cell. The role of CXCL5 in neutrophil attraction is
well established. CXCL5 is the murine equivalent of human
ENA-78, a potent activator of neutrophil function known
to possess neutrophil-activating properties similar to those
of IL-8 [34]. MIG is a CXC chemokine (CXCL9) induced
in diﬀerent cells, including parenchymal cells, endothelial
cells and macrophages, primarily in response to Interferon-
γ (INF-γ) explaining why this chemokine was named
MIG for monokine-induced by Interferon-γ. Curiously,
in our present study, the IL-4-induced MIG production
was transitory and not accompanied by a signiﬁcantly
increased expression of IFN-γ (Table 2). The IL-4-induced
production of sTNFR I suggests that IL-4 may also induce
anti-inﬂammatory signals in parallel. Interestingly, we haveMediators of Inﬂammation 9
previously demonstrated that the proinﬂammatory cytokine
IL-15 induced, in parallel, an anti-inﬂammatory response
based on the production of IL-1Ra [35].
Monocyte chemoattractant protein-1 (MCP-1/CCL2) is
the analyte that has the highest expression after 6 hours of
injection of IL-4 in the pouches. It has been demonstrated
that CCL2 protein expression could be increased under
certain conditions [36]. In contrast, production of CCL2
was also reported to be decreased under other circumstances
[37]. CCL2 is known to be produced by endothelial cells [38]
in response to IL-4 and these cells could be an important
source of this chemokine in our experiments. CCL2 mostly
attracts macrophages and monocytes [39].
Interestingly, a distinct set of analytes was detected in
the supernatants of IL-4-induced lining cells. However, the
increased signals of some analytes, including IFN-γ,I L - 3 ,I -
TAC, leptin, CCL2, MIP-1γ and sTNFR I were common to
bothconditions(IL-4-inducedairpouchesandIL-4-induced
lining cells) when compared with their respective controls.
Of note, IL-4 was found to markedly increase the production
of eotaxin-2, MIG and SDF-1 by these lining cells, indicating
that production of these analytes could be under the control
of a selective mechanism in vivo that is lost in vitro when
these cells are isolated from their natural environment.
This is a good example illustrating the complexity of the
regulation of cytokines and chemokines in vivo in response
to a unique cytokine like IL-4.
The results obtained regarding the expression of CCL2
mRNAinIL-4-inducedMode-K,RAW-264.7,liningandskin
cells, demonstrate further the complexity of the response
occurring after IL-4 treatment and support the role of cells
of diﬀerent origins for attracting neutrophil and monocytic
cell populations in vivo. IL-4 was found to markedly increase
CCL2 mRNA in all tested conditions. The decreased produc-
tion of CCL2 observed after 9 hours (versus 6 hours) could
be explained in part by the increased expression of IL-13
which is known to downregulate the MCP family member’s
production [37]. We also observed that some factors known
to activate or recruit neutrophils are present in the extracts
of pouches that were stimulated with IL-4. For example,
there was an increased expression of keratinocyte cytokine
(KC), a known neutrophil chemoattractant and activator,
and macrophage inﬂammatory protein-1 alpha (MIP-1α),
whichinducessuperoxideproductioninneutrophilsinvitro,
and leptin, known to delay neutrophil apoptosis [40–42].
These three analytes are still detected in greater amounts 12
hours after IL-4 administration, but the ratio of the signal
intensity is less than 1.5.
In conclusion, this study provides the ﬁrst evidence that
IL-4promotestherecruitmentofneutrophilsandmonocytic
cells in vivo by an indirect mechanism. We propose that the
IL-4R positive murine air pouch resident cells (including
lining + skin cells), are the ﬁrst cells to be activated by
IL-4 and that these cells will induce the production of
diﬀerent analytes in the exudates, some of which will attract
neutrophils that will participate, as do monocytes, in the
local production of analytes leading to the attraction of other
neutrophils and/or monocytes.
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